Primary Technology: Early Screening for Gynecological Cancers
Swift Biotechnology licensed a USA Mitchell Cancer Institute technology, which exploits a unique set of protein biomarkers to screen and diagnose early-stage endometrial and ovarian cancer. Benefits of early detection include a 4-fold increase in five year survival rate, and savings of billions in healthcare costs associated with late-stage diagnosis.
Mitchell Cancer Institute, Suite 3014 1660 Springhill Ave.
Mobile, AL 36604
Office: (251) 272-4095
News Link: http://www.swiftbiotechnology.com/?cat=4